PHILADELPHIA, Dec. 22, 2016 /CNW/ -- With 65% of drug development failures occurring because the wrong target was selected, researchers need intelligence to support their next choice. Providing this sophisticated business intelligence is why Drug Research Advisor – Target Druggability, a new tool from Clarivate Analytics, was selected as one of five finalists in the Fierce Innovation Awards, Life Sciences Edition, in the Data Analytics/Business Intelligence category.
Considering the many factors presenting as opportunities for the next development of a first- or best-in-class treatment, researchers are regularly challenged to rapidly evaluate the target landscape surrounding an indication or pathway. The new Target Druggability tool delivers quick, potential targets for a disease of interest. By understanding which targets are associated with a particular disease, if they have drugs associated with them, and at what stage of development they have progressed, researchers are better able to identify where the best scientific opportunities may exist.
The Target Druggability tool utilizes multiple data sets, and its results are displayed for each individual target so that users can uncover knowledge about a selected target condition and its related evidence. Results are then linked to specific conditions of the target and include a variety of information about drugs – ones that act against the target, genetic evidence, biomarker uses and animal model data. Putting this all together provides valuable insights to inform a researchers' understanding of that target, including the likelihood of translation into humans.
"With almost 200 submissions for the Fierce awards, being one of the five finalists in the Data Analytics/Business Intelligence category is quite an honor," said Leo Lafferty-Whyte, Head of Discovery & Translational Science Products for Clarivate Analytics. "Fierce has an established name in the Life Sciences industry and to have our new product recognized prior to its official launch reinforces our belief in the ultimate value it will bring to research, not only with its intelligent insights and analytics, but also in its time savings."
Drug Research Advisor – Target Druggability is expected to be ready for early access to some in January, with its full launch expected in March of 2017.
FierceMarkets, a division of Questex, LLC, is a leader in B2B e-media, providing information and marketing services in the telecommunications, life sciences, healthcare, IT, energy, government, finance, and retail industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets' wide array of digital publications reaches more than 2 million executives in more than 100 countries.
Clarivate™ Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas faster. Formerly the Intellectual Property and Science business of Thomson Reuters, we own and operate a collection of leading subscription-based businesses focused on scientific and academic research, patent analytics and regulatory standards, pharmaceutical and biotech intelligence, trademark protection, domain brand protection and intellectual property management. Clarivate™ Analytics is now an independent company with over 4,000 employees, operating in more than 100 countries and owns well‐known brands that include Web of Science™, Cortellis™, Thomson Innovation™, Derwent World Patents Index™, CompuMark™, MarkMonitor®, Thomson IP Manager™ and Techstreet™, among others. For more information, please visit us at Clarivate.com.
SOURCE Clarivate Analytics
For further information: Media Contact: Heidi Siegel, Clarivate Analytics, Director, External Relations, +1 215 823 5646 (o), +1 215 356 4504 (m), email@example.com, http://Clarivate.com